Kyntra Bio, Inc.
KYNB
$6.82
-$0.19-2.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -179.08% | 1,274.41% | 51.09% | 114.09% | 131.98% |
| Total Depreciation and Amortization | -97.73% | -74.02% | -71.70% | -60.12% | -81.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 171.11% | -479.48% | -68.99% | -50.50% | -110.89% |
| Change in Net Operating Assets | 89.87% | -4,925.99% | 154.85% | 83.40% | -279.21% |
| Cash from Operations | 39.84% | 77.95% | 131.81% | 104.59% | -66.29% |
| Capital Expenditure | 100.00% | 89.02% | 7.14% | 44.83% | 43.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3,605.61% | -- | -- | -- | -84.20% |
| Cash from Investing | -3,101.28% | 11,444.37% | -100.02% | -100.03% | -83.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -50.00% | -503,350.00% | 137.50% | 58.33% | 92.59% |
| Issuance of Common Stock | -- | -- | -- | -- | -48.89% |
| Repurchase of Common Stock | 42.86% | 89.19% | 84.21% | 75.82% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -380.00% | -67,551.18% | -128.13% | 46.67% | 102.03% |
| Foreign Exchange rate Adjustments | 43.68% | 35.71% | -61.95% | 530.94% | -107.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -143.20% | 80.78% | -61.00% | 150.57% | -298.91% |